What does PKI stand for?

Besides rheumatoid arthritis, protein kinase inhibitors are being evaluated in organ transplantation, inflammatory bowel disease, and psoriasis.

Protein kinase inhibitors were also present as indicated.

Topics include natural products, cancer cell proteomics using molecular aptamers, systems biology, high- throughput flow cytometry, Microsoft Excel as a laboratory data management tool, simultaneous screening of multiple cell lines using the CellCard system, protein x-ray crystallography, biological and chemistry assays, monitoring and targeting protein-protein interactions, coupled luminescent methods, combinatorial chemistry, herbal medicines and animal models of gastrointestinal diseases, endocrine and metabolic agents, respiratory viruses, strategies in the design of antiviral drugs, protein kinase inhibitors in drug discovery, RNA-based therapies, novel imaging agents for molecular magnetic resonance imaging of cancer, and targets and approaches for cancer drug discovery.

Targeted Therapy Strategies in Cancer: * Apoptosis * Angiogenesis/VDA/VTA * Antibodies * Immunomodulators & Vaccines * Protein Kinase Inhibitors Each report subject covers: * Compound strategies based on sub-cellular localization of cancer drug targets * The Cancer Genome Project and cancer drug targets * Expression levels of identified drug targets in selected tumor type * Pathway analysis of cancer drug targets * Target-target interactions among identified cancer targets * Structure-based drug design is stimulated by available structure data on biological targets * Unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.

In the near future, other agents such as anti-IL 6 (Actemra) and protein kinase inhibitors will add to the treatment regimen.

com/research/353e6c/analytical_tool) has announced the addition of the "Analytical Tool - Protein Kinase Inhibitors in Oncology 2009" report to their offering.

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs.

Market outlook: our general forecast for the direction and success of protein kinase inhibitors.